- Home
- XBIT vs CHRS Comparison
XBIT vs CHRS Comparison
Compare XBIT & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBIT
- CHRS
- Stock Information
- Founded
- XBIT 2005
- CHRS 2010
- Country
- XBIT United States
- CHRS United States
- Employees
- XBIT N/A
- CHRS N/A
- Industry
- XBIT Pharmaceuticals and Biotechnology
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- XBIT Health Care
- CHRS Health Care
- Exchange
- XBIT Nasdaq
- CHRS Nasdaq
- Market Cap
- XBIT 89.6M
- CHRS 84.2M
- IPO Year
- XBIT 2015
- CHRS 2014
- Fundamental
- Price
- XBIT $3.17
- CHRS $0.76
- Analyst Decision
- XBIT
- CHRS Buy
- Analyst Count
- XBIT 0
- CHRS 3
- Target Price
- XBIT N/A
- CHRS $4.68
- AVG Volume (30 Days)
- XBIT 190.1K
- CHRS 1.3M
- Earning Date
- XBIT 08-11-2025
- CHRS 08-07-2025
- Dividend Yield
- XBIT N/A
- CHRS N/A
- EPS Growth
- XBIT N/A
- CHRS N/A
- EPS
- XBIT N/A
- CHRS N/A
- Revenue
- XBIT N/A
- CHRS $272,251,000.00
- Revenue This Year
- XBIT N/A
- CHRS N/A
- Revenue Next Year
- XBIT N/A
- CHRS $106.56
- P/E Ratio
- XBIT N/A
- CHRS N/A
- Revenue Growth
- XBIT N/A
- CHRS 19.87
- 52 Week Low
- XBIT $2.50
- CHRS $0.66
- 52 Week High
- XBIT $8.32
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- XBIT 64.23
- CHRS 46.35
- Support Level
- XBIT $2.58
- CHRS $0.72
- Resistance Level
- XBIT $2.78
- CHRS $0.77
- Average True Range (ATR)
- XBIT 0.17
- CHRS 0.04
- MACD
- XBIT 0.05
- CHRS 0.00
- Stochastic Oscillator
- XBIT 90.54
- CHRS 38.69
About XBIT XBiotech Inc.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.